You are here: Industry Insights > HCC

News List

HCC Therapeutic Regimens Rewritten by Tumor Immunotherapies: the 12 Years from Sorafenib to Tumor Immunotherapies PharmaSources/1℃
March 18, 2020
Opdivo kicked off the era of HCC immunotherapies in the world, and AiRuiKa’s taking the lead in receiving the approval for HCC indication in China was an important milestone!
U.S. Food and Drug Administration approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) for patients with hepatocellular carcinoma (HCC) previously treated with sorafenib worldpharmanews
March 12, 2020
Bristol Myers Squibb Company announced that Opdivo (nivolumab) 1 mg/kg plus Yervoy (ipilimumab) 3 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) to treat hepatocellular carcinoma (HCC) in patients ...
Lipophilic Statins May Cut Liver Cancer in Chronic Viral Hepatitis drugs
August 21, 2019
Lipophilic statin use is associated with significantly reduced hepatocellular carcinoma (HCC) incidence and mortality in adults with chronic viral hepatitis...
Aspirin May Improve Liver Function After Embolization of HCC drugs
August 13, 2019
Aspirin therapy can improve liver function and survival in patients who have received chemoembolization or transarterial embolization for hepatocellular carcinoma...
BMS’ Opdivo fails to reach primary endpoint in HCC pharmaceutical-technology
June 26, 2019
Bristol Myers-Squibb (BMS) has announced that its blockbuster cancer drug Opdivo (nivolumab) has failed to reach its primary endpoint in the Phase III CheckMate-459 trial.
SIRT is better tolerated than sorafenib, but doesn’t increase overall survival in HCC europeanpharmaceuticalreview
May 07, 2019
Results of the SARAH trial demonstrate that SIRT resulted in median overall survival (OS) of 8.0 months compared to 9.9 months with sorafenib (p=0.179)…
Phenformin-mTOR inhibitor combination shows promise in HCC europeanpharmaceuticalreview
April 22, 2019
A combination of mTOR inhibitors and Phenformin leads to an increase in overall survival…
Risk Factors Identified for Late Recurrence of Liver Cancer drugs
December 14, 2018
Late recurrence after hepatocellular carcinoma (HCC) resection is associated with sex, cirrhosis, and several aggressive tumor characteristics of the initial HCC ......
Nature Review: Current Situation of the Global Liver Cancer Drug Market Weiyi
December 11, 2018
Liver cancer has become one of the tumors with high fatality rate among cancers in the U.S., and is mainly treated through systemic palliative care in the advanced stage.
LSK BioPharma and Jiangsu Hengrui Medicine Announce Global Clinical Collaboration pharmafocusasia
December 04, 2018
LSK BioPharma, a US-based biopharmaceutical firm and Jiangsu Hengrui Medicine, Co., Ltd., one of the largest and most innovative fully-integrated biopharmaceutical companies based in China.....

Previous page 1 2 3 4 Next page